Suter L, Bröcker E B, Brüggen J, Ruiter D J, Sorg C
Cancer Immunol Immunother. 1983;16(1):53-8. doi: 10.1007/BF00199906.
Monoclonal antibodies were generated against established melanoma cell lines and characterized by their reactivity with various sublines. The antibodies selected for their reaction with melanoma-associated antigens were tested on cryostat sections of melanoma tissue from various stages and on other tumors. The reactivity with normal tissues was also determined. Of 30 antibodies reacting with melanoma cell lines 11 did not react with melanoma biopsies. Of the remaining 19 antibodies nine displayed broad cross-reactivity with normal cells and structures and other benign or malignant tumor cells. Among the remaining antibodies five types were defined that detected antigens (nevocellular I, nevocellular II, neural, endothelial, basal cell) found on certain normal tissues and structures and on certain tumor phenotypes. Even though there seems to be a tendency for some antigens to be preferentially associated with certain stages of melanoma, it has not yet been possible to establish any clear-cut correlation between the expression of one of the differentiation antigens and a particular stage or malignancy potential of melanoma.
针对已建立的黑色素瘤细胞系产生了单克隆抗体，并通过它们与各种亚系的反应性进行了表征。选择与黑色素瘤相关抗原发生反应的抗体，在来自不同阶段的黑色素瘤组织的冷冻切片以及其他肿瘤上进行测试。还确定了它们与正常组织的反应性。在与黑色素瘤细胞系发生反应的30种抗体中，有11种与黑色素瘤活检组织不发生反应。在其余的19种抗体中，有9种与正常细胞、结构以及其他良性或恶性肿瘤细胞表现出广泛的交叉反应性。在其余的抗体中，定义了五种类型，它们可检测在某些正常组织、结构以及某些肿瘤表型上发现的抗原（痣细胞I、痣细胞II、神经、内皮、基底细胞）。尽管某些抗原似乎有优先与黑色素瘤特定阶段相关联的趋势，但尚未能够在一种分化抗原的表达与黑色素瘤的特定阶段或恶性潜能之间建立任何明确的相关性。
